Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Kangqian Biotechnology Limited has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The company's prosecution footprint is currently limited to 1 distinct examiner and 1 distinct art unit. This suggests a targeted approach to patenting, likely centered on a single core technology or a specific biological discovery. The concentration in 1 distinct art unit indicates that the subject matter falls within a specific pharmaceutical or biotech category.
HUMPHRIES, NICHOLAS ADAM is the busiest examiner, holding 1 busiest examiner pending action. Given that the total pending office actions and the busiest examiner pending count are each 1, this examiner is the only official currently reviewing the company's applications. The presence of only 1 distinct examiner means that the outcome of the portfolio's current prosecution phase depends on the interactions with this official. Practitioners should analyze the past decisions of HUMPHRIES, NICHOLAS ADAM to better understand the likely trajectory of this single pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUMPHRIES, NICHOLAS ADAM | 1 | 34.2% | +76.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18004623 | COMPOSITIONS AND METHODS FOR INHIBITING YTHDF1 | HUMPHRIES, NICHOLAS ADAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18004623 | COMPOSITIONS AND METHODS FOR INHIBITING YTHDF1 | HUMPHRIES, NICHOLAS ADAM | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18004623 | COMPOSITIONS AND METHODS FOR INHIBITING YTHDF1 | HUMPHRIES, NICHOLAS ADAM | 1631 | §103§112 | Non-Final OA | — | Pending | Jan 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Kangqian Biotechnology Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nicholas Adam Humphries has the most, with 1 of Shanghai Kangqian Biotechnology Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.